Allarity Therapeutics, Inc. filed a Form 8-K on November 17, 2026, disclosing an Exchange Agreement dated November 12, 2026, under which the company partitioned a $3,000,000 promissory note from an existing note and exchanged it for 3,000 shares of newly designated Series B Preferred Stock issued to Streeterville Capital, LLC.

Key Highlights

  • Exchange Agreement: Allarity Therapeutics and Streeterville Capital, LLC entered into an Exchange Agreement on November 12, 2026, partitioning a $3,000,000 note from the original $10,930,000 Promissory Note A-1 dated March 2, 2026.
  • Exchange Shares issued: On November 16, 2026, the company issued 3,000 shares of Series B Preferred Stock to Streeterville in exchange for the surrender and cancellation of the Partitioned Note.
  • No cash proceeds: According to the filing, "The Company received no cash proceeds from the exchange, and Streeterville provided no consideration other than the surrender of the Partitioned Note."
  • Aggregate Stated Value: The 3,000 Exchange Shares carry an aggregate initial Stated Value of $3,150,000, with each share having an initial stated value of $1,050.
  • Preferred return rate: Each share of Series B Preferred Stock accrues a preferred return at 9% per annum, compounded daily, payable quarterly in cash or additional Series B Preferred Stock at the company's election.
  • No conversion right: The Certificate of Designation does not provide for conversion of the Series B Preferred Stock into shares of the company's common stock.
  • ATM Side Letter: A separate Side Letter provides Streeterville's conditional consent to future at-the-market common stock sales, requiring the company to pay Streeterville 33% of net proceeds settled each week such sales occur.

Allarity Therapeutics Restructures Streeterville Note Into Series B Preferred Stock

According to the Form 8-K filed with the SEC, Allarity Therapeutics (NASDAQ:ALLR) entered into an Exchange Agreement with Streeterville Capital, LLC on November 12, 2026. The agreement partitioned a new promissory note in the principal amount of $3,000,000 from the existing Promissory Note A-1, which had an original principal amount of $10,930,000 and was dated March 2, 2026. The outstanding balance of the A-1 Note was reduced by $3,000,000 as a result. The partition became effective upon acceptance of the Certificate of Designation by the Secretary of State of the State of Delaware, and the exchange closed on November 16, 2026.

In connection with the exchange, the company's Board of Directors approved a Certificate of Designation on November 12, 2026, designating 5,000 shares of Series B Preferred Stock with an initial stated value of $1,050 per share. The filing states that the Series B Preferred Stock ranks senior to common stock and other junior capital stock with respect to dividends, distributions, and payments upon liquidation. The preferred stock carries no general voting rights and does not vote with the common stock, though holders of a majority of outstanding Series B Preferred Stock must provide prior written consent before the company may amend the Certificate of Designation or authorize capital stock ranking senior to or pari passu with the Series B Preferred Stock.

The Certificate of Designation imposes operating covenants on the company while any Series B Preferred Stock remains outstanding. These include maintaining Exchange Act reporting status and a listing of common stock on Nasdaq, the New York Stock Exchange, or NYSE American, as well as restrictions on additional debt and equity issuances, asset pledges, and certain fundamental transactions. If an Event of Default occurs and remains uncured for five trading days, the preferred return increases to 15% per annum and holders may elect a one-time 15% increase in the Stated Value. The Side Letter separately permits at-the-market common stock sales with Streeterville's consent, subject to a 33% sweep of weekly net proceeds directed toward redemption of Series B Preferred Stock or repayment of the A-1 Note.

What Was Disclosed

Allarity Therapeutics disclosed the entry into an Exchange Agreement and a Side Letter with Streeterville Capital, LLC, the issuance of 3,000 Series B Preferred Stock shares with an aggregate stated value of $3,150,000, and the terms of the newly designated preferred stock series, including its 9% preferred return rate, senior ranking, covenant restrictions, and Event of Default provisions.